Primary sclerosing cholangitis: Overview and update

Flavia Mendes, Keith Lindor

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disorder that most commonly affects middle-aged men. PSC is strongly associated with IBD, and in this setting the risk of colorectal cancer is markedly increased. Cholangiocarcinoma, and its devastating consequences, is another well-recognized complication of PSC. This condition tends to progress to end-stage liver disease, and patients with PSC have reduced survival rates compared with the general population. Despite significant research efforts in this field, the pathogenetic mechanisms of PSC are still incompletely understood, although growing evidence supports the role of genetic and immunologic factors. Effective medical therapy is lacking; liver transplantation is the only curative treatment modality, with excellent outcomes in this patient population.

Original languageEnglish (US)
Pages (from-to)611-619
Number of pages9
JournalNature Reviews Gastroenterology and Hepatology
Volume7
Issue number11
DOIs
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

Sclerosing Cholangitis
End Stage Liver Disease
Cholangiocarcinoma
Immunologic Factors
Liver Transplantation
Population
Colorectal Neoplasms
Survival Rate
Liver
Therapeutics
Research

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Primary sclerosing cholangitis : Overview and update. / Mendes, Flavia; Lindor, Keith.

In: Nature Reviews Gastroenterology and Hepatology, Vol. 7, No. 11, 11.2010, p. 611-619.

Research output: Contribution to journalArticle

@article{f37716d798084b15a9f57e4f6e9e544c,
title = "Primary sclerosing cholangitis: Overview and update",
abstract = "Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disorder that most commonly affects middle-aged men. PSC is strongly associated with IBD, and in this setting the risk of colorectal cancer is markedly increased. Cholangiocarcinoma, and its devastating consequences, is another well-recognized complication of PSC. This condition tends to progress to end-stage liver disease, and patients with PSC have reduced survival rates compared with the general population. Despite significant research efforts in this field, the pathogenetic mechanisms of PSC are still incompletely understood, although growing evidence supports the role of genetic and immunologic factors. Effective medical therapy is lacking; liver transplantation is the only curative treatment modality, with excellent outcomes in this patient population.",
author = "Flavia Mendes and Keith Lindor",
year = "2010",
month = "11",
doi = "10.1038/nrgastro.2010.155",
language = "English (US)",
volume = "7",
pages = "611--619",
journal = "Nature Reviews Gastroenterology and Hepatology",
issn = "1759-5045",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Primary sclerosing cholangitis

T2 - Overview and update

AU - Mendes, Flavia

AU - Lindor, Keith

PY - 2010/11

Y1 - 2010/11

N2 - Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disorder that most commonly affects middle-aged men. PSC is strongly associated with IBD, and in this setting the risk of colorectal cancer is markedly increased. Cholangiocarcinoma, and its devastating consequences, is another well-recognized complication of PSC. This condition tends to progress to end-stage liver disease, and patients with PSC have reduced survival rates compared with the general population. Despite significant research efforts in this field, the pathogenetic mechanisms of PSC are still incompletely understood, although growing evidence supports the role of genetic and immunologic factors. Effective medical therapy is lacking; liver transplantation is the only curative treatment modality, with excellent outcomes in this patient population.

AB - Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disorder that most commonly affects middle-aged men. PSC is strongly associated with IBD, and in this setting the risk of colorectal cancer is markedly increased. Cholangiocarcinoma, and its devastating consequences, is another well-recognized complication of PSC. This condition tends to progress to end-stage liver disease, and patients with PSC have reduced survival rates compared with the general population. Despite significant research efforts in this field, the pathogenetic mechanisms of PSC are still incompletely understood, although growing evidence supports the role of genetic and immunologic factors. Effective medical therapy is lacking; liver transplantation is the only curative treatment modality, with excellent outcomes in this patient population.

UR - http://www.scopus.com/inward/record.url?scp=78049530861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049530861&partnerID=8YFLogxK

U2 - 10.1038/nrgastro.2010.155

DO - 10.1038/nrgastro.2010.155

M3 - Article

C2 - 20938459

AN - SCOPUS:78049530861

VL - 7

SP - 611

EP - 619

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

SN - 1759-5045

IS - 11

ER -